Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
The annual meeting of stockholders of Crinetics Pharmaceuticals, Inc. (the “Company”) was held online via live audio webcast on June 7, 2024 (the “Annual Meeting”). At the Annual Meeting, there were present, virtually or by proxy, holders of 78,744,364 shares of common stock, or approximately 86% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting are as follows:
Proposal One - Election of Directors
The Company’s stockholders approved the election of two Class III directors to the Board of Directors for three year terms to expire at the 2027 annual meeting of stockholders. The results of such vote were:
|
Votes For |
Votes Withheld |
Broker Non-Votes |
||
Camille Bedrosian, M.D. |
50,829,173 |
|
14,947,321 |
|
2,328,910 |
Wendell Wierenga, Ph.D. |
50,300,772 |
|
15,475,722 |
|
2,328,910 |
Proposal Two - Ratification of Selection of Independent Registered Accounting Firm
The Company’s stockholders ratified the selection of BDO USA, P.C. as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2024. The results of such vote were:
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
67,973,983 |
|
115,422 |
|
15,999 |
|
0 |
Proposal Three - Approval, on an advisory basis, of the compensation of the Company’s named executive officers
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were:
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
64,052,127 |
|
1,745,589 |
|
6,019 |
|
2,301,669 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Crinetics Pharmaceuticals, Inc. |
|
|
|
|
Date: |
June 10, 2024 |
By: |
/s/ R. Scott Struthers, Ph.D. |
|
|
|
R. Scott Struthers, Ph.D. |